CAS 380843-75-4
:Bosutinib
Description:
Bosutinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of chronic myelogenous leukemia (CML). It selectively inhibits the BCR-ABL fusion protein, which is responsible for the proliferation of cancer cells in CML. Bosutinib has a molecular formula that reflects its complex structure, featuring multiple functional groups that contribute to its pharmacological activity. The compound is characterized by its ability to inhibit not only BCR-ABL but also other kinases, which may lead to a broader spectrum of effects. It is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. Common side effects associated with bosutinib include gastrointestinal disturbances, hematologic abnormalities, and liver enzyme elevations. Its efficacy and safety profile make it a valuable option in the therapeutic landscape for patients with resistant or intolerant forms of CML. As with all medications, monitoring for adverse effects and drug interactions is essential during treatment.
Formula:C26H29Cl2N5O3
InChI:InChI=1/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
InChI key:InChIKey=UBPYILGKFZZVDX-UHFFFAOYSA-N
SMILES:N(C=1C2=C(C=C(OCCCN3CCN(C)CC3)C(OC)=C2)N=CC1C#N)C4=CC(OC)=C(Cl)C=C4Cl
Synonyms:- 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-Methoxyphenyl)amino]-6-Methoxy-7-[3-(4-Methyl-1-piperazinyl)propoxy]-
- 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methylpiperazin-1-Yl)Propoxy]Quinoline-3-Carbonitrile
- 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
- Bosulif
- Kin 001-160
- Sk 606
- Ski-606
- Bosutinib
- Bosutinib for research
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 12 products.
Ref: IN-DA00BXOO
1g129.00€1mg29.00€25g590.00€50gTo inquire100gTo inquire10mg53.00€100mg58.00€250mg91.00€Bosutinib
CAS:Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.Formula:C26H29Cl2N5O3Purity:98.98% - 99.9%Color and Shape:Yellowish-Orange Or Pink To Brownish Solid Solid PowderMolecular weight:530.45Bosutinib
CAS:Formula:C26H29Cl2N5O3Purity:(HPLC) ≥ 98.0%Color and Shape:Light yellow to yellow powderMolecular weight:530.45Bosutinib
CAS:Formula:C26H29Cl2N5O3Purity:>95.0%(T)(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:530.45Bosutinib Impurity 14
CAS:Formula:C10H8Cl2N2O2Color and Shape:Pale Yellow SolidMolecular weight:259.09Bosutinib
CAS:Inhibitor of Abl and Src kinases; anti-proliferative; antineoplasticÂFormula:C26H29Cl2N5O3Purity:Min. 95%Color and Shape:Off-White PowderMolecular weight:530.45 g/mol1-Methyl-4-propylpiperazine Bosutinib
CAS:Controlled Product<p>Applications 4-((2,4-Dichloro-5-methoxyphenyl)(3-(4-methylpiperazin-1-yl)propyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile is an impurity of Bosutinib (B676095). It is a COVID19-related research product.<br></p>Formula:C34H45Cl2N7O3Color and Shape:NeatMolecular weight:670.6725,6-Dihydroxy-Des(dimethoxy) Bosutinib
CAS:Controlled ProductFormula:C24H25Cl2N5O3Color and Shape:NeatMolecular weight:502.393Bosutinib
CAS:Drugs containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structureFormula:C26H29Cl2N5O3Molecular weight:529.16475










